Close Menu

Mesa Biotech

The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.

Bringing testing closer to patients could be helpful, provided enough tests and instruments can be manufactured and distributed.

The 30-minute PCR assay, read visually, uses the company's Accula system, which is designed for use at the point of care.

The test is the fourth COVID-19 molecular diagnostic to be awarded funding from BARDA. Others include Hologic, Qiagen, and DiaSorin Molecular.

The firm will be validating the test with collaborators in China, and plans to pursue Emergency Use Authorization both in China and the US.

In US influenza testing, providers see growth in placements within hospital emergency departments, physicians' offices, urgent care centers, and retail clinics.

The test combines the superior performance of laboratory-based PCR tests and the simplicity and convenience of traditional POC rapid immunoassays, the firm said.

This test is the firm's second assay on the point-of-care Accula molecular diagnostics system. 

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.